3 ms·
Sure. They were able to demonstrate to the FDA's satisfaction that it had a beneficial use outside the original intent of developing the drug. That's not unusua
by ceejayoz 5y ago
Sure. They were able to demonstrate to the FDA's satisfaction that it had a beneficial use outside the original intent of developing the drug. That's not unusual, but there's also a procedure you go through.
The FDA specifically warns against using ivermectin to treat COVID. So does its manufacturer (https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/ https://www.merck.com/news/merck-statement-on-ivermectin-use...). Comparing the two scenarios is silly.
- mizzack 5y agoMerck is expecting to rake in billions on sales of molnupiravir. Ivermectin is off patent.